Clinical and morphological aspects of the combination of tuberculosis and lung cancer
##article.numberofdownloads## 43
##article.numberofviews## 334
pdf (Русский)

Keywords

lung cancer
pulmonary tuberculosis
diagnostics

How to Cite

Stogova, N. (2022). Clinical and morphological aspects of the combination of tuberculosis and lung cancer. Voprosy Onkologii, 68(1), 75–79. https://doi.org/10.37469/0507-3758-2022-68-1-75-79

Abstract

The purpose of the study. To establish the features of clinical and radiological manifestations of the disease and the effectiveness of methods of examination of patients with a combination of lung cancer and tuberculosis.

Material and methods. The analysis of the case histories of 38 lung cancer patients aged 42 to 82 years, 31 men and 7 women who were in the Voronezh regional tuberculosis dispensary in 1995–2019 was carried out. In 20 patients, cancer was combined with active pulmonary tuberculosis (group 1) and in 18 patients with inactive residual changes in the lungs after earlier tuberculosis (group 2). Research methods: clinical, laboratory, instrumental, morphological, statistical using the SPSS Statistics 10 program.

Results. In group 1, focal pulmonary tuberculosis in the infiltration phase was detected in 2 (10.0%), infiltrative tuberculosis — in 18 (90.0%) patients. Central lung cancer was found in 12 (60.0%), peripheral — in 8 (40.0%) patients. Lung cancer was detected in stage I in 5 (25.0%), in stage II in 6 (30.0%), in stage III in 4 (20.0%) and in stage IV in 5 (25.0%) patients. In group 2, central lung cancer was detected in 7 (38.9%), peripheral lung cancer in 11 (61.1%) patients. Lung cancer was detected in stage I in 3 (16.7%), in stage II in 2 (11.1%), in stage III in 3 (16.7%) and in stage IV in 10 (55.5%) patients.

Conclusion. The combination of lung cancer and tuberculosis is more often observed in men, more often in the elderly and senile age. Cancer occurs in the lung on the side of the tuberculous lesion with active tuberculosis in 75.0%, with inactive — in 83.3% of cases. Microbiological and morphological methods of investigation are the most effective for verifying the diagnosis of a combination of tuberculosis and lung cancer.

https://doi.org/10.37469/0507-3758-2022-68-1-75-79
##article.numberofdownloads## 43
##article.numberofviews## 334
pdf (Русский)

References

Корецкая Н.М., Лесунова И.В. Клиническая картина и диагностика рака легкого у лиц пожилого и старческого возраста с остаточными туберкулезными изменениями // Успехи геронтологии. 2011;24(3):456–459. doi://old.gerontology.ru/PDF_YG/AG_2011-24-03.pdf [Koretskaya NM, Lesunova IV. Clinical picture and diagnosis of lung cancer in elderly and senile patients with residual tuberculosis changes // Uspekhi gerontologii. 2011;24(3):456–459. (In Russ.)]. doi://old.gerontology.ru/PDF_YG/AG_2011-24-03.pdf

Sisti J, Boffetta P. What proportion of lung cancer in never-smokers can be attributed to known risk factors? // Int. J. Cancer. 2012;131:265–275. doi:10.1002/ijc.27477

Морозова О.А., Захаренков В.В., Виблая И.В., Морозов В.П. Факторы риска развития и естественное течение рака легкого у лиц в возрасте до 50 лет // Медицина в Кузбассе. 2014;13(2):27–31. doi://cyberleninka.ru/article/n/faktory-riska-razvitiya-i-estestvennoe-techenie-raka-legkogo-u-lits-v-vozraste-do-50-let/viewer [Morozova OA, Zakharenkov VV, Viblaya IV, Morozov VP. Risk factors of development and natural course of lung cancer in persons under 50 years old // Meditsina v Kuzbasse, 2014;13(2):27–31. (In Russ.)]. doi://cyberleninka.ru/article/n/faktory-riska-razvitiya-i-estestvennoe-techenie-raka-legkogo-u-lits-v-vozraste-do-50-let/viewer

Leung CY, Huang HL, Rahman MM et al. Cancer incidence attributable to tuberculosis in 2015: global, regional, and national estimates // BMC Cancer. 2020;20(1):412. doi:10.1186/s12885-020-06891-5

Yamaguchi F, Minakata T, Miura S et al. Heterogeneity of latent tuberculosis infection in a patient with lung cancer // J. Infect. Public Health. 2020;13(1):151–153. doi:10.1016/j.jiph.2019.07.009

Jin C, Yang B. A case of delayed diagnostic pulmonary tuberculosis during targeted therapy in an EGFR mutant non-small cell lung cancer patient // Case Rep. Oncol. 2021;14(1):659–663. doi:10.1159/000514050

Fijołek J, Wiatr E, Polubiec-Kownacka M et al. Pulmonary tuberculosis mimicking lung cancer progression after 10 years of cancer remission // Adv. Respir. Med. 2018;86(2):92–96. doi:10.5603/ARM.2018.0012

Chen CH, Huang CY, Chow SN. Early-stage ovarian carcinoma combined with pulmonary tuberculosis mimicking advanced ovarian cancer: a case report // Int. J. Gynecol. Cancer. 2004;14(5):1007–11. doi:10.1111/j.1048-891X.2004.014543.x

Endri M, Cartei G, Zustovich F et al. Differential diagnosis of lung nodules: breast cancer metastases and lung tuberculosis // Infez. Med. 2010;18(1):39–42. doi://pubmed.ncbi.nlm.nih.gov/20424525/

Hakami A, Zwartkruis E, Radonic T, Daniels JMA. Atypical bronchial carcinoid with postobstructive mycobacterial infection: case report and review of literature // BMC Pulm. Med. 2019;19(1):41. doi:10.1186/s12890-019-0806-x

Плотников В.П., Перминова И.В., Черных Е.Е., Лаптев С.П. Случай сочетания рака лёгкого и фиброзно-кавернозного туберкулёза лёгких // Туберкулёз и болезни лёгких. 2019;97(1):35–40. doi:10.21292/2075-1230-2019-97-1-35-40 [Plotnikov VP, Perminova IV, Chernykh EE, Laptev SP. A case of a combination of lung cancer and fibrous-cavernous pulmonary tuberculosis // Tuberculyes i bolezni lyegkikh. 2019;97(1):35–40 (In Russ.)]. doi: 10.21292/2075-1230-2019-97-1-35-40

Nalbandian A, Yan BS, Pichugin A et al. Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control // Oncogene. 2009;28(17):1928–38. doi:10.1038/onc.2009.32

Gupta PK, Tripathi D, Kulkarni S, Rajan MG. Mycobacterium tuberculosis H37Rv infected THP-1 cells induce epithelial mesenchymal transition (EMT) in lung adenocarcinoma epithelial cell line (A549) // Cell Immunol. 2016;300:33–40. doi:10.1016/j.cellimm.2015.11.007

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2021